Search

Displaying results 1601 - 1610 of 10000 in total
  1. Drug

    Phenmetrazine

    go.drugbank.com/drugs/DB00830
    ApprovedIllicit

    A sympathomimetic drug used primarily as an appetite depressant. Its actions and mechanisms are similar to dextroamphetamine.

  2. Drug

    Ozanimod

    go.drugbank.com/drugs/DB12612
    ApprovedInvestigational

    in MS therapy. … [L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020.

  3. Drug

    Trifarotene

    go.drugbank.com/drugs/DB12808
    ApprovedInvestigational

    Trifarotene is a topical retinoid cream used in the treatment of acne vulgaris that was first approved for use in the United States in October 2019. … ] Trifarotene is considered the first of the "fourth-generation" retinoids due to its uniquely selective activity - this selectivity appears to confer improved efficacy and reduced side effects as compared

    Categories: Retinoids for Topical Use in Acne
  4. Drug

    Gefapixant

    go.drugbank.com/drugs/DB15097
    Approved

    It received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications. … [L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601]

  5. Drug

    Nandrolone decanoate

    go.drugbank.com/drugs/DB08804
    ApprovedIllicitInvestigational

    effect compared to nandrolone and other esters. … Nandrolone decanoate, also known as nandrolone caprinate, is an alkylated anabolic steroid indicated in the management of anemia of renal insufficiency and as an adjunct therapy in the treatment of senile

  6. Drug

    Milnacipran

    go.drugbank.com/drugs/DB04896
    ApprovedInvestigational

    important role in the mitigation of pain signals in the descending inhibitory pain pathways in the brain and spinal cord [A175759, A175843, A175846]. … Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment

  7. Drug

    Catumaxomab

    go.drugbank.com/drugs/DB06607
    ApprovedWithdrawn

    Its market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency. … Catumaxumab was approved for market in Canada in May 2012 for the same condition [FDA Label]. It is currently available under the brand name Removab.

  8. Drug

    Remoxipride

    go.drugbank.com/drugs/DB00409
    ApprovedWithdrawn

    [A215422] It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512] … Remoxipride is an atypical antipsychotic agent that is specific for dopamine D<sub>2</sub> receptors.

  9. Drug

    Difelikefalin

    go.drugbank.com/drugs/DB11938
    ApprovedInvestigational

    Difelikefalin (CR845) is an agonist of kappa opioid receptors (KORs) useful in the treatment of pruritus secondary to chronic kidney disease. KORs were first associated with itching in 1984. … [A237615,A237620] The clinical burden of uremic pruritus in this patient population is being increasingly recognized as contributing to a significant reduction in patient quality of life, poor outcomes

  10. Drug

    Lecanemab

    go.drugbank.com/drugs/DB14580
    ApprovedInvestigational

    [A253947,A253957] In clinical trials, it significantly reduced brain Aβ plaques compared to placebo. … [A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023.